We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cancer/testis antigens can be immunological targets in clonogenic CD133<sup>+</sup> melanoma cells.
- Authors
Gedye, Craig; Quirk, Juliet; Browning, Judy; Svobodová, Suzanne; John, Thomas; Sluka, Pavel; Dunbar, P. Rod; Corbeil, Denis; Cebon, Jonathan; Davis, Ian D.
- Abstract
“Cancer stem cells” that resist conventional treatments may be a cause of therapeutic failure in melanoma. We report a subpopulation of clonogenic melanoma cells that are characterized by high prominin-1/CD133 expression in melanoma and melanoma cell lines. These cells have enhanced clonogenicity and self-renewal in vitro, and serve as a limited in vitro model for melanoma stem cells. In some cases clonogenic CD133+ melanoma cells show increased expression of some cancer/testis (CT) antigens. The expression of NY-ESO-1 in an HLA-A2 expressing cell line allowed CD133+ clonogenic melanoma cells to be targeted for killing in vitro by NY-ESO-1-specific CD8+ T-lymphocytes. Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma.
- Subjects
ANTIGENS; CANCER cells; CELL lines; IMMUNOLOGICAL adjuvants; IMMUNOTHERAPY
- Publication
Cancer Immunology, Immunotherapy, 2009, Vol 58, Issue 10, p1635
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-009-0672-0